Clinical implications of genomic alterations in metastatic prostate cancer.

Abstract excerpt

There has been a rapid expansion in treatment options for the management of metastatic prostate cancer, but individual patient outcomes can be variable due to inter-patient tumor heterogeneity. Fortunately, the disease can be stratified on the basis of common somatic features, providing potential for the development of clinically useful prognostic and predictive biomarkers. Tissue biopsy programs and studies...

Topics

Join the communities discussing this publication.

• Biomarkers, Tumor
• Circulating Tumor DNA
• Genomics
• Molecular Targeted Therapy
• Mutation